Processa Pharmaceuticals, Inc.
PCSA· Nasdaq
PCSAProcessa Pharmaceuticals, Inc.
Filed Aug 5, 2020 · 10-Q · 36 days after period end · 0001493152-20-014712
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Net Income | -$733.41K | -$969.08K | -$1.21M | -$42.85K |
| EPS Diluted | -$0.13 | -$0.18 | -$0.03 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Jun 30, 2020 · filed Aug 5, 2020 · 36 d after period end
